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Abstract 
Purpose:  Asthma exacerbations are a leading cause of hospital and emergency department admissions at pediatric institutions.  The 
objective of this study was to determine if patients who obtain discharge medications from a pediatric institution’s outpatient 
pharmacy after an admission for asthma have a lower thirty-day readmission rate than those who do not obtain discharge 
medications from the outpatient pharmacy.  Methods: This multi-phase retrospective study included an initial chart review, an 
intervention period, and a second chart review of the intervention period. The chart reviews included patients ages two years and 
older with a discharge diagnosis of asthma or wheezing. During the intervention phase, pharmacists promoted use of the outpatient 
pharmacy by patients admitted for these conditions using multiple methods. In each chart review, the patients readmitted for 
asthma or wheezing within thirty days were classified as either outpatient pharmacy users (OPP users) or non-OPP users. Differences 
in readmission rates between OPP users and non-OPP users, as well as differences in overall OPP utilization, were analyzed before 
and during the intervention phase using a Chi-square test.  Results: The initial chart review found no significant difference in thirty 
day readmission rates between OPP users and non-OPP users (6.2% and 7.5%, respectively; χ
2
 = 1.15; p = 0.274). The number of OPP 
users increased significantly from the first chart review to the second (11.8% and 45.9%, respectively; χ
2
 = 929.04, p < 0.001). The 
second chart review revealed that OPP users had a significantly lower readmission rate than non-OPP users during the intervention 
phase (2.3% and 10.9%, respectively; χ
2
 = 52.5; p < 0.001). Conclusion: Obtaining discharge medications from the OPP was associated 
with a lower thirty-day readmission rate in children with asthma. Promoting use of the OPP for transitional care should continue to 
be part of future efforts to decrease hospital readmissions. 
 
 
Background 
In recent years, researchers have identified the need for 
health care providers and public health officials to improve 
clinical outcomes in pediatric asthma by addressing gaps in 
access to care, seizing opportunities for improvements in the 
health care system, and examining asthma-related 
hospitalizations.
1-3
 Inpatient (IP) hospitalizations are one 
potential result of an exacerbation of asthma, which is a 
chronic inflammatory condition of the airways. Exacerbations 
also may lead to missed days of school and work for the child 
and parent, impaired daily functions and quality of life, 
emergency department (ED) visits, or death.
1,4-6
  According to 
the National Health Interview Survey, the prevalence of 
asthma in children less than 18 years old has increased from 
8.7% to 9.6% from 2001 to 2009, and is significantly higher 
than in adults.
3
  The goal of treating asthma is to prevent 
morbidity, which is measured by exacerbations and 
progressive deterioration of lung function, and mortality.
7
  
Children who are ethnic minorities, under age five, from low- 
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income households, inner-city residents, or who are exposed 
to tobacco smoke or air pollution have a higher risk of 
experiencing morbidity and mortality from asthma.
1,4,7
 Other 
known risk factors for morbidity and mortality from asthma 
include individuals with an increased frequency and severity 
of past asthma exacerbations, multiple ED visits or IP 
hospitalizations for asthma in the past year, or any history of 
intubation or intensive care unit (ICU) admission for 
asthma.
7,8
 
 
The National Heart, Lung, and Blood Institute (NHLBI) and the 
National Asthma Education and Prevention Program (NAEPP) 
Expert Panel Report 3 clinical guidelines released in 2007 
emphasize the importance of preventative anti-inflammatory 
treatment. Yet, asthma exacerbations continue to be a 
leading cause of pediatric hospitalizations.
3,4,7
 In 2007, there 
were 41.4 hospitalizations and 132.7 ED visits for asthma per 
10,000 children under age five.
9
 The Healthy People 2020 
goal is to significantly reduce these numbers to 18.1 
hospitalizations and 95.5 ED visits per 10,000 children.   
 
The guidelines recommend continued treatment with several 
prescription medications after an exacerbation,
7
 but children 
diagnosed with asthma may have increased barriers to health 
care, including unmet prescription needs.
1,10-13
 Kogan and 
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colleagues (2010) found that children in fair or poor health or 
with special health care needs due to a chronic condition 
(including use of prescription medications) were more likely 
to be underinsured and experience barriers to appropriate 
health care.
10
  Prescription access for asthmatics is crucial, 
because poor adherence to therapy has been found to be a 
prevalent cause of uncontrolled asthma.
14-18
 Delays in 
obtaining medication could lead to non-adherence, 
uncontrolled asthma, and readmissions.
13,16
  
 
Pharmacists can play a pivotal role in the prevention of 
morbidity and mortality due to asthma.
19
 Education and 
management of asthmatics by pharmacists has been shown 
to improve inhaler technique and medication adherence, 
leading to better asthma control and reduced ED and IP 
admissions.
20-24
 Yet, these efforts are not effective unless the 
patient has immediate access to prescription medications. As 
discussed, high-risk asthmatic children, such as those recently 
admitted for an exacerbation, may encounter several barriers 
to obtaining prescription medications. An outpatient 
pharmacy on the hospital campus may be able to eliminate 
some of these barriers by dispensing discharge medications 
to patients before they leave the campus, resulting in better 
initial medication adherence and therefore a lower rate of 
readmission within thirty days, which is equivalent to the 
usual supply of medication dispensed. Therefore, the primary 
objective of this study was to determine if patients who 
obtain first-fill medications from a pediatric institution’s 
outpatient pharmacy after an ED or IP admission for asthma 
have a lower thirty-day readmission rate than patients who 
do not obtain discharge medications from the outpatient 
pharmacy.  The secondary objectives of this study were to 
examine the relationship between selected patient 
characteristics (age, insurance, and type of readmission) and 
OPP utilization for patients readmitted within 30 days. 
 
Methods 
This multiphase, interventional study was conducted at a 
free-standing, tertiary pediatric institution with an on-campus 
outpatient pharmacy. The institution has more than 350 
inpatient beds and treated over 19,000 inpatients and 76,000 
emergency department patients in 2010. The study included 
three components: a pre-intervention retrospective chart 
review, an intervention, and a second retrospective chart 
review.  The timeline (see Figure 1) details several important 
stages of the study. The hospital Institutional Review Board 
(IRB) gave the pre-intervention phase of the study expedited 
approval. The intervention and second chart review were 
considered quality improvement and were exempt from IRB 
review. 
 
 
Pre-Intervention Retrospective Chart Review 
The purpose of the initial chart review was to determine if 
patients who obtained discharge medications from the 
outpatient pharmacy (OPP) had a lower rate of thirty-day 
readmissions than those who did not obtain discharge 
medications from the OPP. Using the institution’s electronic 
medical record (EMR), patients ages two and older admitted 
to the hospital or ED with a principal ICD-9 diagnosis of 
asthma or wheezing from October 2008 through June 2010 
were identified.  Each patient’s chart was analyzed for thirty-
day readmission encounters, which were defined as an IP or 
ED readmission within thirty-days of a prior IP or ED 
admission. The OPP records of patients with thirty-day 
readmission encounters were examined to determine 
whether or not each readmitted patient had used the OPP to 
fill his or her asthma medications within one day of discharge.  
Readmitted patients then were classified into two groups: 
OPP users or non-OPP users.  Finally, the rates of thirty-day 
readmission were calculated for each group and compared. 
 
Intervention 
The intervention was designed to increase the percent of 
asthma patients utilizing the OPP upon discharge. Outpatient 
pharmacists performed educational interventions with 
patients’ families and clinical staff to encourage utilization of 
the OPP.  This effort, called Don’t Leave Without Them, was 
part of a hospital-wide initiative to decrease asthma 
admissions and took place from July 2010 to February 2011.  
Monday through Friday, pediatric inpatients being treated for 
asthma exacerbations were identified by outpatient 
pharmacists via a consult order that was sent through the 
EMR. The pharmacists visited each patient and their family 
members at least once during their admission to educate the 
family about the OPP and distribute a promotional card 
detailing the services offered by the OPP, as well as its 
location and hours of operation. Questions from the 
patient/family were common, and often led to informal 
discussions about medications, but no formal medication or 
disease state education was performed. Occasionally, the 
pharmacists were unable to make contact with a patient or 
family during their admission. If the family chose to use the 
OPP, the card acted as a reminder to their nurse to ensure 
prescriptions were sent accordingly. In the ED, flyers 
promoting the OPP were distributed to patients upon 
admission by registration staff. These flyers served the same 
purpose as the cards given to inpatients, but were not 
complemented by a personal visit from a pharmacist.  
 
Collaboration with nurses, respiratory therapists, medical 
staff, discharge coordinators, and other hospital staff was 
essential for the success of this program.  Interventions 
aimed at educating staff about the purpose of Don’t Leave 
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Without Them were continuous and focused on the units that 
treated the majority of asthma exacerbations, due to the 
large number of clinical staff. The outpatient pharmacists 
were in regular communication with the clinical leaders of 
these units and worked with them to distribute weekly 
updates on the program’s progress to their clinical staff.  
Although the program was driven by two outpatient 
pharmacists, several non-pharmacy clinicians and staff were 
champions for the program, including discharge coordinators 
who regularly called the outpatient pharmacists to let them 
know which patients were going home that day, physicians, 
nurse leaders, and administrators.  
 
Second Retrospective Chart Review  
Thirty day readmission rates were reassessed to determine 
the impact of the intervention phase using a retrospective 
chart review with the same inclusion criteria and methods as 
the initial chart review, but for the time frame of the 
intervention phase (July 2010 to February 2011). The thirty-
day readmission rates were again calculated for each group 
and compared to determine if there was a difference in the 
thirty-day readmission rates between OPP users and non-OPP 
users. 
 
Statistical Analyses 
All data were analyzed using IBM SPSS v. 20.0 for Windows 
(Armonk, New York). An a priori level of 0.05 was used for 
statistical significance. Descriptive statistics were used to 
examine OPP use, thirty-day readmissions (ED and IP), age, 
and insurance type (private and Medicaid).  Differences in 
readmission rates, type of readmission (ED or IP), age (<4 
years, 5-11 years, and ≥12 years), and insurance status 
(private or Medicaid) between OPP users and non-OPP users, 
as well as differences in overall OPP utilization, were analyzed 
before and during the intervention phase using a Chi-squared 
or Kruskal-Wallis test as appropriate.   
 
Results 
Pre-Intervention Retrospective Chart Review 
The first phase of the study evaluated 4,903 encounters that 
met inclusion criteria, occurring from October 2008 to June 
2010.  Only 578 of these encounters (11.8%) were OPP users 
(see Table 1). OPP users had a lower thirty day readmission 
rate than non-OPP users.  However, the relationship between 
OPP-utilization and readmission rate was not statistically 
significant (6.2% and 7.5%, respectively; χ
2
 = 1.15; p = 0.274) 
(Table 2). 
 
Second Retrospective Chart Review   
The number of OPP users during the intervention phase was 
45.9%, an increase from 11.8% pre-intervention.  The 
relationship between OPP-utilization and study phase was 
statistically significant (Table 1; χ
2
 = 929.04; p < 0.001). A total 
of 1,824 encounters were analyzed using a retrospective 
chart review at the end of the intervention, revealing 127 
thirty-day readmissions (Table 1). Overall, thirty-day 
readmission rates in the study population were similar at pre-
intervention (7.3%) and at the second retrospective chart 
review (7.5%).  However, there was a statistically significant 
relationship between OPP-utilization and 30 day readmission 
rates (Table 2; χ
2
 = 52.49; p < 0.001).  OPP users had a lower 
readmission rate than non-OPP users in the second 
retrospective chart review (2.3% and 10.9%, respectively). 
 
Differences in Readmission by Selected Characteristics 
Of patients readmitted within 30 days, there were differences 
in type of readmission by OPP utilization (Table 3).  There was 
a statistically significant relationship between OPP-utilization 
and admission type during the pre-intervention phase (χ
2
 = 
20.79; p<0.001) and at the second retrospective chart review 
(χ
2
 = 8.67; p=0.007).  OPP users had lower emergency 
department and inpatient admission rates than non-OPP 
users in the pre-intervention phase.  Within 30 day 
readmissions, there were no significant relationships 
between OPP-utilization and age or insurance type (Table 3). 
 
Differences in age and insurance status according to type of 
admission also were analyzed for patients readmitted within 
30 days (Table 4).  There was a statistically significant 
relationship between type of admission and OPP-utilization in 
patients less than 4 years old who were readmitted within 30 
days during the intervention phase (χ
2
=10.58; p=0.007) and 
patients ages 5-11 who were readmitted within 30 days 
during the pre-intervention phase (χ
2
=31.93; p<0.001).  There 
were lower emergency department readmission rates in 
pediatrics less than 4 years old who utilized the OPP 
pharmacy during the intervention phase and ages 5-11 who 
utilized the OPP pharmacy during the pre-intervention phase.  
There were no other significant differences by age.   
 
There also was a statistically significant relationship between 
admission type and OPP-utilization in patients with Medicaid 
as their primary insurer who were readmitted within 30 days 
in both the pre-intervention (χ
2
=23.86; p<0.001) and 
intervention (χ
2
=11.08; p=0.001) phases. Of patients who 
were readmitted with Medicaid insurance, there were less 
OPP-users than non-OPP users during pre-intervention (7.3% 
for OPP users, 92.7% for OPP non-users) and at the second 
retrospective chart review (11.4% for OPP users, 88.6% for 
OPP non-users).  There were no other statistically significant 
differences by insurance type. 
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Discussion 
Results from the second retrospective chart review indicated 
that the Don’t Leave Without Them program significantly 
increased OPP utilization rates, and children who were 
discharged from an ED or IP visit for an asthma exacerbation 
and picked up discharge medications from the OPP were 
significantly less likely to be readmitted within thirty days.  In 
the pre-intervention chart review, there were no statistically 
significant differences between OPP users and non-OPP users 
with regard to readmission rates.  However, non-OPP users 
did have higher readmission rates.   
 
The difference between readmission rates from the pre-
intervention chart review to the second retrospective chart 
review was likely due to the significant increase in the 
percent of these patients utilizing the OPP, not a change in 
practice. The efforts of the pharmacists during the 
intervention were mainly focused on communication, 
education, and marketing. The actual practices of the 
pharmacy did not change during the intervention, but more 
patients were receiving the benefits that the pharmacy 
offers.  By increasing the utilization of the OPP, there were 
enough OPP users to detect differences.  Post-hoc power 
analyses indicated the pre-intervention retrospective chart 
review did not provide sufficient power to detect statistical 
differences, assuming an effect size of 0.1.  A sample size of 
785 OPP users was needed to detect differences at the 80% 
power level, which was achieved through the intervention for 
the second retrospective chart review (N=836).   
 
There are many reasons why OPP users may have had a lower 
rate of 30-day readmissions.  As previously discussed, 
pediatric asthmatics may be at increased risk to encounter 
barriers to obtaining the prescription medications they need 
to prevent exacerbations.
1,10-13
 Patients who utilize the OPP 
are able to avoid several of these barriers. The OPP is easily 
accessible to those already on the hospital campus, and is 
open into the evenings and during the day on weekends to 
accommodate patients discharged at those times. The OPP 
offers a billing service which ensures that patients are able to 
take their medications home that day without any delays due 
to gaps in insurance coverage or ability to pay. The patients 
who utilize this service may not have been able to get their 
medications in a timely manner or at all at another pharmacy. 
The OPP also counsels every family when they pick up their 
medications. Counseling by a pharmacist can make a great 
impact in asthma due to complex inhaler administration 
techniques and confusion over the purpose of each 
medication.
19-24
 Although other community pharmacists are 
capable of providing this teaching, they may not act on their 
intent to provide asthma counseling to pediatric patients due 
to barriers (e.g. lack of time, lack of parent interest, no 
placebo devices).
25
 The OPP pharmacists and interns are 
trained to work in pediatric medicine and have access to the 
patient’s EMR and are able to easily contact providers to 
make necessary recommendations. They also have access to 
medical interpreters to serve the institution’s diverse patient 
base. Overall, the continuity of care provided by the OPP 
likely decreases barriers to obtaining first-fill medications and 
increases medication adherence, thereby resulting in lower 
readmission rates.  
 
The results of this study may be especially relevant due to the 
location of the hospital and the population it serves. As 
addressed previously, children with asthma who are ethnic 
minorities, from low-income households, inner-city residents, 
or who are exposed to tobacco smoke or air pollution are at 
higher risk for morbidity and mortality.
1,4,7
 The hospital  is 
located in the inner-city and over 20% of the OPP’s patients 
are from the zip codes surrounding the hospital. In 2008, an 
average of 47% of the households in these five zip codes had 
an income < $25,000.
26
 Of note, over 50% of patients who 
utilize the OPP have state Medicaid insurance. Also, patients 
in the study had at least one asthma exacerbation, which 
meant they were at risk for future exacerbations and hospital 
readmissions.
7,8
 Any change in practice, such as the 
intervention proposed in this study, that could decrease 
readmissions in high-risk populations would be beneficial and 
should be further investigated. 
 
The results from the secondary objectives identified a few 
sub-groups of the population that should be focused on due 
to their higher than expected rates of readmission. First, ED 
patients who were non-OPP users had higher rates of 
readmission in both phases. Since Don’t Leave Without Them 
focused heavily on inpatients, the higher rates of readmission 
in ED patients were not unexpected. Lower rates of OPP use 
in ED patients may also be attributed to the hours of 
operation of the OPP, which is not open during the overnight 
hours. It is very possible that since ED visits are patient/family 
directed as opposed to physician directed, there is a need for 
asthma management education in this population. Looking at 
non-OPP ED patients by age we see that children ≤ 4 years old 
had significantly higher readmissions than their counterparts 
who were OPP users. This shows that there is a great 
potential to prevent readmissions in this patient population if 
they use the OPP. Non-OPP ED patients aged 5-11 years had 
higher than expected readmissions in the first phase but not 
the second, which shows that readmissions in this age group 
may not be as dependent on OPP use as the younger 
population.  Another group that had higher than expected 
readmission rates in both phases was ED, non-OPP users with 
Medicaid.  Future research should focus interventions 
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specifically aimed towards ED patients, specifically those ≤ 4 
years old and those with Medicaid as the primary payer.  
 
There were several limitations to this analysis. Picking up 
prescriptions at the OPP was used as a measure of adherence 
to medication, but there are many other factors which could 
affect adherence, such as: medication availability and 
acquisition from other sources (i.e., home supply, another 
pharmacy), lack of proper inhaler technique, and patients 
who pick up medication but do not use it. Readmissions to 
urgent care centers or other institutions were not 
investigated. Furthermore, the clinical appropriateness of 
discharge therapy was not assessed, although it is monitored 
closely by the OPP pharmacists upon dispensing.   
 
Conclusion 
In conclusion, this study found that providing discharge 
medications from a pediatric hospital’s outpatient pharmacy 
to children with asthma exacerbations may be linked with 
decreased rates of readmission within thirty-days.  This could 
be attributed to increased adherence to medication therapy 
and the continuity of care facilitated by the OPP.  In addition, 
several groups were identified as target groups for future 
efforts to decrease readmissions: ED patients; ED patients ≤ 4 
years old; and ED patients with Medicaid. 
 
The results should not be applied to readmissions beyond 
thirty days, as this is the usual day supply of medication 
dispensed, and there is no reason to believe that the benefit 
of utilizing an on-campus pharmacy would extend beyond the 
supply of the medication. These results apply specifically to 
pediatric tertiary care centers with outpatient pharmacies, 
but future research is needed to determine the impact of 
similar programs at other institutions that provide acute care 
to individuals requiring medication therapy to prevent 
chronic illness exacerbations.  While the study was not 
designed to determine a causal relationship between OPP use 
and thirty-day readmission rates, it  provides evidence that 
promoting the use of the OPP for transitional care should 
continue to be part of future efforts to decrease 
readmissions, and can serve as a model for other institutions.  
While the official initiative at this hospital ended in March 
2011, the efforts have been on-going due to the success of 
the program. 
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Table 1.  Differences in Utilization of Outpatient Pharmacy Services (OPP) by Intervention Phase 
 
 Pre-Intervention Phase 
N=4903 
N (%) 
Intervention Phase 
N=1821 
N (%) 
Pearson Chi-
Square 
Significance 
OPP Users 578 (11.8) 836 (45.9) 
929.04 p < 0.001 
Non-OPP Users 4325 (88.2) 987 (54.1) 
 
 
 
 
 
 
 
Table 2.  Differences in 30-Day Readmission Rates by Outpatient Pharmacy Service (OPP) Utilization 
 
 
Pre-Intervention Phase 
30-Day Readmission 
Intervention Phase 
30-Day Readmission 
 Yes 
N (%) 
No 
N (%) 
Pearson 
Chi-
Square 
Significance 
Yes 
N (%) 
No 
N (%) Pearson 
Chi-Square 
Significance 
OPP 
Users 
36 (6.2) 542 (93.8) 
1.20 0.274 
19 (2.3) 817 (97.7) 
52.49 < 0.001 Non-OPP 
Users 
324 (7.5) 4001 (92.5) 108 (10.9) 879 (89.1) 
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Table 3.  Differences in 30-Day Readmissions by Selected Characteristics and Outpatient Pharmacy Service (OPP) Utilization 
 
 Pre-Intervention Phase 
Patients Readmitted within 30 Days 
Intervention Phase 
Patients Readmitted within 30 Days 
OPP User 
N (%) 
Non-OPP  
N (%) 
Pearson 
Chi-Square 
Significance 
OPP User 
N (%) 
Non-OPP 
N (%) 
Pearson 
Chi-Square 
Significance 
Admission Type         
 Emergency 
Department 
20 (6.7) 278 
(93.3) 
20.79 < 0.001 
11 (10.6) 93 (89.4) 
8.67 0.007 
 Inpatient 16 (25.8) 46 (74.2) 8 (34.8) 15 (65.2) 
Age 
  Kruskal-
Wallis Test 
Significance   
Kruskal-
Wallis Test 
Significance 
 ≤4 years 15 (12.4) 106 
(87.6) 
1.34 0.247 
7 (15.9) 37 (84.1) 
0.02 0.894 
 5-11 years 15 (10.2) 132 
(89.8) 
6 (12.2) 43 (87.8) 
 ≥12 years 6 (7.3) 76 (92.7) 6 (17.6) 28 (82.4) 
Insurance Type   
Pearson 
Chi-Square 
Significance   
Pearson 
Chi-Square 
Significance 
 Private 4 (4.8) 79 (95.2) 
3.63 0.057 
2 (7.7) 24 (92.3) 
1.518 0.218  Medicaid 31 (12.2) 224 
(87.8) 
17 (17.5) 80 (82.5) 
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Table 4.  Differences in 30-Day Readmissions by Age, Primary Payer and Outpatient Pharmacy Service (OPP) Utilization 
 
   Pre-Intervention Phase 
Patients Readmitted within 30 Days 
Intervention Phase 
Patients Readmitted within 30 Days 
Age Type of 
Admission 
OPP 
User 
N (%) 
Non-OPP 
N (%) 
Pearson 
Chi-
Square 
Significance OPP 
User 
N (%) 
Non-OPP 
N (%) 
Pearson 
Chi-
Square 
Significance 
 ≤4 years Emergency 
Department 
12 
(11.0) 
97 (89.0) 1.65 0.199 3 (10.5) 34 (91.9) 10.58 0.007 
  Inpatient 3 (25.0) 9 (75.0) 4 (57.1) 3 (42.9) 
 5-11 
years 
Emergency 
Department 
4 (3.4) 115 
(96.6) 
31.93 <0.001 4 (10.3) 35 (89.7) 0.70 0.402 
  Inpatient 11 
(39.3) 
17 (60.7) 2 (20.0) 8 (80.0) 
 ≥12 years Emergency 
Department 
4 (6.7) 56 (93.3) 0.14 0.709 4 (14.3) 24 (85.7) 1.23 0.267 
  Inpatient 2 (9.1) 20 (90.9) 2 (33.3) 4 (66.7) 
Primary 
Payer 
         
 Private Emergency 
Department 
4 (5.7) 66 (94.3) 0.78 0.377 2 (9.1) 20 (90.9) 0.394 0.530 
  Inpatient 0 (0.0) 13 
(100.0) 
0 (0.0) 4 (100.0) 
 Medicaid Emergency 
Department 
15 (7.3) 191 
(92.7) 
23.86 <0.001 9 (11.4) 70 (88.6) 11.08 0.001 
  Inpatient 16 
(32.7) 
33 (67.3) 8 (44.4) 10 (56.4) 
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